Allogene Therapeutics slides after ASH presentation disappointment

 

• Allogene Therapeutics (ALLO -13.3%) slumps as investors appear disappointed to interim results from Phase 1 trial, UNIVERSAL, evaluating ALLO-715, anti-CD52 monoclonal antibody with ALLO-647 lymphodepletion, for relapsed/refractory multiple myeloma. Data were presented at the American Society of Hematology annual meeting.
• 31 patients were evaluable for safety and 26 patients were evaluable for efficacy as of data cutoff of October 30.
• Overall median follow-up for efficacy was 3.2 months and six out of the nine patients treated with DL3 (320M) or DL4 (480M) with a response remain in response. The longest response was ongoing at six months from the DL3 cohort with FCA lymphodepletion.
• Data demonstrated 60% overall response rate with higher cell dose (320M) and FCA lymphodepletion; 40% achieved a very good partial response or better.
• https://seekingalpha.com/news/3642141-allogene-therapeutics-slides-after-ash-presentation-disappointment